Fisher & Paykel Healthcare: executive options lapse on unmet conditions

Fisher & Paykel Healthcare Corporation Limited announced on September 5, 2025, that 412,417 options and 130,857 performance share rights to acquire ordinary shares, issued on September 4, 2020, have lapsed. This lapse was due to unmet vesting conditions, which were part of the company's discretionary long-term variable remuneration plans.

A related disclosure from Andrew Robert Donald Somervell, vice president - products & technology, detailed the impact on his holdings. Before the lapse, he held 144,531 options to acquire ordinary shares and 70,182 performance share rights. After the lapse, his holdings decreased to 124,441 options and 63,810 performance share rights, indicating a lapse of 20,090 options and 6,372 performance share rights for him.

The company's products are sold in over 120 countries, focusing on acute and chronic respiratory care, surgery, and obstructive sleep apnea treatment. The announcement was authorized by Raelene Leonard, general counsel and company secretary.